

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L6</u>	(cd20) same (antibod\$) and(cd40L or cd40 adj ligand) same (antibod\$) and (lymphoma\$ or hodgkin\$)same (treat\$ or inhibit\$ or suppress\$ or prevent\$ or therap\$ or prevent\$)	69	<u>L6</u>
<u>L5</u>	(cd20) same (cd40L or cd40 adj ligand) and (lymphoma\$ or hodgkin\$)	30	<u>L5</u>
<u>L4</u>	(cd20) and (cd40L or cd40 adj ligand) and (lymphoma\$ or hodgkin\$)	300	<u>L4</u>
<u>L3</u>	L2 and (cd40L or cd40 adj ligand)	10	<u>L3</u>
<u>L2</u>	L1 and (cd20)	34	<u>L2</u>
<u>L1</u>	hanna-nabil\$	67	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

There are more results than shown above. [Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L6

[Refine Search](#)[Recall Text](#) ⇌[Clear](#)**Search History**

DATE: Thursday, August 28, 2003 [Printable Copy](#) [Create Case](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 10 returned.**

-
- ☐ 1. [20030103971](#). 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
-
- ☐ 2. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
-
- ☐ 3. [20020058029](#). 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. [Hanna, Nabil](#). 424/131.1; 424/144.1 A61K039/395.
-
- ☐ 4. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. [Hanna, Nabil](#), et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
-
- ☐ 5. [20020006404](#). 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. [Hanna, Nabil](#), et al. 424/142.1; 424/155.1 A61K039/395.
-
- ☐ 6. [20010018041](#). 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. [Hanna, Nabil](#), et al. 424/1.49; 424/181.1 A61K039/395.
-
- ☐ 7. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 8. [6440418](#). 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 9. [6001358](#). 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.53. A61K039/395 C07K016/28.
-
- ☐ 10. [WO 2060485 A2](#). 31 Jan 02. 08 Aug 02. IMMUNOREGULATORY ANTIBODIES AND USES THEREOF. HARIHARAN, KANDASAMY, et al. A61K045/00; A61K045/06 A61K039/395 A61P035/00 A61P035/02.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
(2 AND (CD40L OR (CD40 ADJ LIGAND))).USPT,PGPB,JPAB,EPAB,DWPI.	10
(L2 AND (CD40L OR CD40 ADJ LIGAND))).USPT,PGPB,JPAB,EPAB,DWPI.	10

[Previous Page](#)[Next Page](#)

Search Results - Record(s) 1 through 10 of 69 returned.

-
- ☐ 1. 20030158402. 16 Dec 02. 21 Aug 03. Nucleic acids encoding CD100 molecules. Hall, Kathryn T., et al. 536/23.5; 435/320.1 435/325 435/69.1 530/350 C07K014/74 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 2. 20030138881. 20 Dec 01. 24 Jul 03. Novel co-stimulatory molecules. Punnonen, Juha, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C07K014/705 C12P021/02 C12N005/06 C07H021/04.
-
- ☐ 3. 20030133932. 25 Oct 02. 17 Jul 03. Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents. Zhou, Tong, et al. 424/143.1; 424/85.5 514/171 514/251 514/263.31 514/269 514/27 514/283 514/34 514/410 514/49 514/492 514/561 514/575 514/629 514/649 514/733 514/8 A61K038/21 A61K038/16 A61K039/395 A61K031/7072 A61K031/4745 A61K031/704 A61K031/56 A61K031/525 A61K031/522.
-
- ☐ 4. 20030124130. 19 Dec 02. 03 Jul 03. Proteomic analysis of tumors for development of consultative report of therapeutic options. Brown, Robert E.. 424/155.1; 435/7.23 702/19 G01N033/574 G06F019/00 G01N033/48 G01N033/50 A61K039/395.
-
- ☐ 5. 20030124122. 26 Apr 02. 03 Jul 03. Simultaneous stimulation and concentration of cells. Berenson, Ronald, et al. 424/144.1; 435/372 A61K039/395 C12N005/08.
-
- ☐ 6. 20030119185. 28 Jun 02. 26 Jun 03. Activation and expansion of cells. Berenson, Ronald, et al. 435/372; C12N005/08.
-
- ☐ 7. 20030119029. 13 Aug 02. 26 Jun 03. Compositions and methods relating to novel benzodiazepine compounds and targets thereof. Glick, Gary D., et al. 435/6; 435/235.1 435/325 514/221 A61K031/5513 C12Q001/68 A61K031/55 A01N043/62 C12N007/00 C12N007/01 C12N005/00 C12N005/02.
-
- ☐ 8. 20030114379. 02 Oct 02. 19 Jun 03. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1). Li, Haodong, et al. 514/12; A61K038/17.
-
- ☐ 9. 20030103971. 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
-
- ☐ 10. 20030099622. 16 Apr 02. 29 May 03. Systems and methods for inducing mixed chimerism. Hering, Bernhard, et al. 424/93.21; 435/366 A61K048/00 C12N005/08.
-

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)

[Next Page](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 69 returned.**

-
- ☐ 11. [20030082806](#). 29 Apr 02. 01 May 03. Maturation of antigen-presenting cells using activated T cells. Berenson, Ronald Jay, et al. 435/372; 424/93.21 A61K048/00 C12N005/08.
-
- ☐ 12. [20030082575](#). 19 Apr 02. 01 May 03. In vivo incorporation of unnatural amino acids. Schultz, Peter, et al. 435/6; 435/252.3 435/254.2 435/325 435/348 435/419 435/69.1 435/91.2 C12Q001/68 C12P019/34 C12P021/02 C12N001/21 C12N001/18 C12N005/06 C12N005/04.
-
- ☐ 13. [20030077273](#). 17 May 02. 24 Apr 03. Methods of treating antibody-mediated pathologies using agents which inhibit CD21. Linnik, Matthew D., et al. 424/131.1; 424/144.1 A61K039/395.
-
- ☐ 14. [20030077247](#). 19 Sep 02. 24 Apr 03. Chemokines as adjuvants of immune response. Caux, Christophe, et al. 424/85.1; 424/185.1 424/204.1 424/234.1 424/274.1 424/85.2 A61K038/19 A61K038/20 A61K039/00 A61K039/12 A61K039/02.
-
- ☐ 15. [20030054363](#). 29 Oct 01. 20 Mar 03. Compositions and methods for the therapy and diagnosis of lung cancer. Henderson, Robert A., et al. 435/6; 435/183 435/320.1 435/325 435/69.1 435/7.23 536/23.2 C12Q001/68 G01N033/574 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
-
- ☐ 16. [20030044416](#). 09 Nov 95. 06 Mar 03. NUCLEIC ACIDS ENCODING CD100 MOLECULES. HALL, KATHRYN T., et al. 424/184.1; 435/320.1 435/325 514/12 530/324 530/350 536/23.5 A61K039/00 C07K016/00 A61K038/00 A61K039/38 C07K014/00 C07H021/04 C07H021/02 C12N015/00 C12N015/09 C12N015/63.
-
- ☐ 17. [20030021797](#). 02 Aug 02. 30 Jan 03. Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus. Datta, Syamal K., et al. 424/185.1; 435/199 435/320.1 435/325 435/69.1 530/358 536/23.5 A61K039/00 C07H021/04 C12N009/22 C12P021/02 C12N005/06.
-
- ☐ 18. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
-
- ☐ 19. [20030003097](#). 02 Apr 02. 02 Jan 03. Recombinant antibodies coexpressed with GnTIII. Reff, Mitchell E., et al. 424/144.1; 435/334 530/388.22 A61K039/395 C12N005/06 C07K016/30.
-
- ☐ 20. [20020197256](#). 14 Mar 02. 26 Dec 02. Combination therapy. Grewal, Iqbal. 424/144.1; 424/155.1 A61K039/395.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 30 of 69 returned.**

-
- ☐ 21. 20020176855. 12 Feb 99. 28 Nov 02. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT THEREWITH. CO, MAN SUNG, et al. 424/133.1; 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/252.3 435/320.1 435/326 435/328 435/334 . 435/343 435/346 435/440 435/455 435/69.6 530/387.3 530/388.1 530/388.22 530/388.73 536/23.1 536/23.4 536/23.53 C07H021/02 A61K039/40 C07H021/04 C12P021/04 A61K039/395 A61K039/42 C12N015/09 C12N001/20 C12N015/00 C12N015/63 C12N015/70 C12N015/74 C12N005/16 C12N005/06 C12N015/85 C12N005/00 C12N005/12 C12P021/08 C07K016/00 C12N015/87.
-
- ☐ 22. 20020172952. 10 Jul 01. 21 Nov 02. Compositions and methods for the therapy and diagnosis of lung cancer. Henderson, Robert A., et al. 435/6; 435/183 435/320.1 435/325 435/69.1 435/7.23 536/23.2 C12Q001/68 G01N033/574 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
-
- ☐ 23. 20020147312. 30 Jan 02. 10 Oct 02. Hybrid antibodies and uses thereof. O'Keefe, Theresa, et al. 530/387.3; 530/388.15 C07K016/28.
-
- ☐ 24. 20020119568. 20 Sep 01. 29 Aug 02. Simultaneous stimulation and concentration of cells. Berenson, Ronald, et al. 435/446; 435/285.1 435/372 435/376 C12N015/01 C12M001/00 C12N005/08.
-
- ☐ 25. 20020119150. 09 Apr 02. 29 Aug 02. Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection. Kirk, Allan D., et al. 424/144.1; A61K039/395.
-
- ☐ 26. 20020115112. 15 Aug 01. 22 Aug 02. Neutrokin-alpha and Neutrokin-alpha splice variant. Yu, Guo-Liang, et al. 435/7.2; 424/145.1 530/388.23 C07K016/24 G01N033/567 G01N033/53 A61K039/395.
-
- ☐ 27. 20020106736. 25 Sep 01. 08 Aug 02. Human tumor necrosis factor receptor TR17. Ruben, Steven M., et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C07K014/705 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 28. 20020058029. 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. Hanna, Nabil. 424/131.1; 424/144.1 A61K039/395.
-
- ☐ 29. 20020058019. 26 Feb 01. 16 May 02. Simultaneous stimulation and concentration of cells. Berenson, Ronald, et al. 424/93.7; 435/372 A61K045/00 C12N005/08.
-
- ☐ 30. 20020039557. 20 Jun 01. 04 Apr 02. Treatment of B-cell associated diseases such as malignances and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination. White, Christine. 424/1.49; 424/143.1 A61K051/00 A61K039/395.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 31 through 40 of 69 returned.**

-
- ☐ 31. [20020031522](#). 10 Mar 97. 14 Mar 02. TRUNCATED CRAFI INHIBITS CD40 SIGNALING. BALTIMORE, DAVID, et al. 424/185.1; 435/63 435/64 435/7.2 435/7.23 530/324 530/350 530/358 G01N033/53 G01N033/567 G01N033/574 C12P031/00 C12P029/00 A61K039/00 C07K005/00 C07K007/00 C07K016/00 C07K017/00 A61K038/00 C07K001/00 C07K014/00 A61K038/16.
-
- ☐ 32. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
-
- ☐ 33. [20020019018](#). 25 Jun 01. 14 Feb 02. Assay to detect a binding partner. Christopherson, Richard Ian, et al. 435/7.23; G01N033/574.
-
- ☐ 34. [20020009726](#). 09 Jan 01. 24 Jan 02. CD40 associated proteins. Reed, John C., et al. 435/6; 435/325 435/69.1 435/7.23 530/350 530/388.1 536/23.5 C12Q001/68 G01N033/574 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 35. [20020009444](#). 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.
-
- ☐ 36. [20020006404](#). 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.
-
- ☐ 37. [20020004587](#). 20 Mar 01. 10 Jan 02. Multivalent antibodies and uses therefor. Miller, Kathy L., et al. 530/388.8; 424/143.1 435/325 435/334 536/23.5 C07K016/28 A61K039/395 C07H021/04 C12N005/06.
-
- ☐ 38. [20010056066](#). 13 Jul 01. 27 Dec 01. Method of treating immune cell mediated systemic diseases. Bugelski, Peter John, et al. 514/8; 424/131.1 A61K038/16 A61K039/395.
-
- ☐ 39. [20010018041](#). 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.
-
- ☐ 40. [6592868](#). 07 Jun 95; 15 Jul 03. Methods for treating autoimmune diseases with 5C8-specific antibodies. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.73 530/388.75. A61K039/395 C07K016/28.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 41 through 50 of 69 returned.**

-
- ☐ 41. [6576754](#). 09 Nov 95; 10 Jun 03. CD100 antigen and uses therefor. Hall; Kathryn T., et al. 536/23.5; 536/23.1. C07H021/04.
-
- ☐ 42. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 43. [6495129](#). 13 Oct 00; 17 Dec 02. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3). Li; Haodong, et al. 424/85.1; 514/12 514/2 514/8. A61K038/19.
-
- ☐ 44. [6492498](#). 15 Nov 99; 10 Dec 02. Multimeric immunotoxins. Vallera; Daniel A., et al. 530/391.7; 424/183.1 530/300 530/350 530/387.1. C07K016/00.
-
- ☐ 45. [6468537](#). 28 Apr 00; 22 Oct 02. Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus. Datta; Syamal K., et al. 424/185.1; 424/184.1 514/13 514/14 514/2 514/866 514/885 530/300 530/325 530/326 530/327. A61K038/04 A61K038/10 A61K038/16 C07K007/08 C07K014/00.
-
- ☐ 46. [6451310](#). 07 Jun 95; 17 Sep 02. Method for inhibiting an allergic response with a 5c8-specific antibody. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 47. [6447767](#). 16 Feb 00; 10 Sep 02. Non-myeloablative tolerogenic treatment. Slavin; Shimon, et al. 424/93.1; 424/93.21 435/325 514/2 514/44. A61K038/00 A61K048/00 C12N015/85.
-
- ☐ 48. [6440418](#). 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 49. [6403091](#). 07 Jun 95; 11 Jun 02. Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/343 435/343.1 435/343.2 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 50. [6368596](#). 08 Jul 98; 09 Apr 02. Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells. Ghetie; Maria-Ana, et al. 424/141.1; 424/130.1 424/133.1 424/134.1 424/136.1 424/138.1 424/139.1 424/142.1 424/152.1 424/155.1 424/156.1 424/172.1. A61K039/395 A61K039/40 A61K039/42.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 51 through 60 of 69 returned.**

-
- ☐ 51. [6297052](#). 24 Apr 97; 02 Oct 01. B cell culture system comprising high density membrane bound CD40 ligand. Kehry; Marilyn, et al. 435/377; 435/2 435/325 435/326 435/346 435/355 435/372 435/372.1 435/372.2 435/375 530/351. C12N005/00 C12N005/02 C07K014/52.
-
- ☐ 52. [6294167](#). 23 Nov 98; 25 Sep 01. Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated. Lindhofer; Horst, et al. 424/93.7; 424/130.1 424/136.1 424/137.1 424/93.71. A01N063/00 A61K039/395.
-
- ☐ 53. [6265556](#). 02 Dec 94; 24 Jul 01. Nucleic acid encoding CD40 associated proteins. Reed; John C., et al. 536/23.1; 435/320.1 435/69.1 435/70.1 536/23.5. C07H021/02 C12N015/00 C12N001/20 C12P021/06.
-
- ☐ 54. [6172187](#). 27 Aug 96; 09 Jan 01. CD40 associated proteins. Reed; John C., et al. 530/350; 530/324 530/351 536/23.1. C07K001/00 A61K038/00 C07H021/02.
-
- ☐ 55. [6001358](#). 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.53. A61K039/395 C07K016/28.
-
- ☐ 56. [5993816](#). 07 Jun 95; 30 Nov 99. Methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5c8-specific antibodies. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.15 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 57. [5877210](#). 05 Jun 95; 02 Mar 99. Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/178.1 424/179.1 424/181.1 435/184 435/244 556/1 556/42 556/44. A01N055/02 A61K039/395 C07F053/00.
-
- ☐ 58. [5876950](#). 26 Jan 95; 02 Mar 99. Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy. Siadak; Anthony W., et al. 435/7.23; 424/133.1 424/135.1 424/144.1 424/154.1 435/343.2 435/7.24 530/387.3 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 59. [5846998](#). 18 Jun 96; 08 Dec 98. Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/617 424/646 435/184 435/326 556/1 556/42 556/44. A01N055/02 A01N059/16 C12N009/99 C07F053/00.
-
- ☐ 60. [5817516](#). 28 Apr 95; 06 Oct 98. Methods for proliferating and differentiating B cells with high density membrane CD40 ligand. Kehry; Marilyn, et al. 435/377; 435/2 435/325 435/366 435/372.2 435/375. C12N005/02 C12N005/08.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 61 through 69 of 69 returned.**

-
- ☐ 61. 5801227. 08 Sep 95; 01 Sep 98. Antibodies to CD40. Fanslow, III; William C., et al. 530/388.73; 435/326 435/328 435/332 435/334 435/343 435/343.1 435/346 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/389.6. C07K016/28 C07K016/18 C12N005/12.
-
- ☐ 62. 5693627. 25 May 95; 02 Dec 97. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/137; 435/184 435/244 514/141 564/12 568/14 568/17. A61K031/66 C12N009/99 C12N001/38 C07F009/02.
-
- ☐ 63. 5674492. 21 Dec 94; 07 Oct 97. Method of preventing or treating disease characterized by neoplastic cells expressing CD40. Armitage; Richard J., et al. 424/144.1; 424/143.1 424/153.1 424/154.1 424/155.1 424/172.1 424/173.1 424/174.1 514/2 514/8. A61K039/395 A61K035/12 A61K038/02.
-
- ☐ 64. 5596072. 01 Feb 93; 21 Jan 97. Method of refolding human IL-13. Culpepper; Janice, et al. 530/351; 424/85.2 435/69.1 530/402 530/412 930/141. C07K001/00 C07K014/54.
-
- ☐ 65. 5583242. 25 May 95; 10 Dec 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 556/44; 556/1 556/114 556/116 556/117 556/42. C07F005/00.
-
- ☐ 66. 5565491. 31 Jan 94; 15 Oct 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/492; 514/499 556/1 556/114 556/116 556/117 556/42 556/44. A61K031/28 A61K031/30 C07F001/08 C07F005/00.
-
- ☐ 67. 5474771. 15 Nov 91; 12 Dec 95. Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same. Lederman; Seth, et al. 424/133.1; 424/130.1 424/144.1 424/153.1 424/154.1 435/343.2 435/70.21 530/388.7 530/388.73 530/388.75. A61K039/00 C07K016/18 C07K016/28 G01N033/53.
-
- ☐ 68. KR 2003031957 A WO 200204021 A1 US 20020006404 A1 US 20020028178 A1 AU 200164612 A EP 1305045 A1 NO 200300128 A. Treating B cell malignancy in subject, by administering immunoregulating or immunomodulating antibody and B cell depleting antibody. HANNA, N, et al. A61K039/395 A61K051/00 C07K016/28 C07K016/32.
-
- ☐ 69. CN 1407901 A WO 200134194 A1 US 20010018041 A1 AU 200122491 A NO 200202174 A EP 1229935 A1 KR 2002072277 A JP 2003513937 W. Treatment of B-cell malignancies uses anti-CD40L antibodies and anti-CD20 antibodies optionally with chemotherapy. HANNA, N, et al. A61K000/00 A61K039/395 A61K041/00 A61K045/00 A61K051/00 A61K051/10 A61P035/00 A61P035/02.
-

[Generate Collection](#)[Print](#)

Term	Documents
CD20	1500
CD20S	0
CD40L	1033
CD40LS	2
CD40	2731
CD40S	0
LIGAND	85879
LIGANDS	60427
ANTIBOD\$	0
ANTIBOD	827
ANTIBODANTIBODA	1
((CD20) SAME (ANTIBOD\$) AND(CD40L OR CD40 ADJ LIGAND) SAME (ANTIBOD\$) AND (LYMPHOMA\$ OR HODGKIN\$)SAME (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB,JPAB,EPAB,DWPI.	69

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)